Identification and Synthesis of Mycalol Analogues with Improved Potency against Anaplastic Thyroid Carcinoma Cell Lines.

J Nat Prod

Istituto di Chimica Biomolecolare, Bio-Organic Chemistry Unit, Consiglio Nazionale delle Ricerche , Via Campi Flegrei 34, 80078, Pozzuoli, Naples, Italy.

Published: April 2017

The marine metabolite mycalol (1) has a specific inhibitory activity on cells of anaplastic thyroid carcinoma (ATC), a very aggressive and rare cancer that does not have effective conventional therapy. In this study, we describe six new related analogues (2-7) that differ in the length of the terminal alkyl residue and the presence of acetate or 3S-hydroxybutyrate (3S)-3HB as a substituent at C-19. Despite the structural analogies, some of the new members were significantly more cytotoxic than 1 on cell lines derived from human ATC. Structures inclusive of the 2'R,3R,4S,7R,8S,19R absolute configuration were assigned to 2-7 on the basis of detailed spectroscopic analysis, synthesis of different isomers, and application of ECD and Mosher's methods. This work led to the identification of mycalol-578 (3) as the most potent analogue, with an IC of 2.3 μM on FRO cells.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jnatprod.7b00043DOI Listing

Publication Analysis

Top Keywords

anaplastic thyroid
8
thyroid carcinoma
8
cell lines
8
identification synthesis
4
synthesis mycalol
4
mycalol analogues
4
analogues improved
4
improved potency
4
potency anaplastic
4
carcinoma cell
4

Similar Publications

Anaplastic thyroid carcinoma (ATC) is an aggressive cancer that requirements rapid diagnosis and multimodal treatment. Next-generation sequencing (NGS) aids in personalized therapies and improved trial enrollment. The role of liquid-based NGS in ATC remains unclear.

View Article and Find Full Text PDF

Anaplastic thyroid cancer (ATC) is a lethal endocrine malignancy. It has been shown that tumor-associated macrophages (TAMs) contribute to the aggressiveness of ATC. However, stimulatory factors that could facilitate the induction and infiltration of TAMs in the ATC tumor microenvironment (TME) are not fully elucidated.

View Article and Find Full Text PDF

In the endocrine system, anaplastic thyroid cancer (ATC) is extremely aggressive since it inhibits the majority of medications and treatments. Therefore, there is an immediate demand to identify new treatment approaches or drugs to deal with ATC. Recently, amino acid Schiff base copper complexes have received great attention due to their excellent anti-tumor activity.

View Article and Find Full Text PDF

Alectinib treatment for 2 non-small cell lung carcinoma patients carrying different novel fusions.

Zhong Nan Da Xue Xue Bao Yi Xue Ban

July 2024

Department of Pathology, Second Xiangya Hospital, Central South University, Changsha 410011.

The genomic fusions of the anaplastic lymphoma kinase () gene have been widely recognized as effective therapeutic targets for non-small cell lung carcinoma (NSCLC). The Second Xiangya Hospital of Central South University has treated 2 NSCLC patients with 2 distinct novel gene fusions. Case 1 was a 55-year-old male with a solid nodule located in the right hilar lobe on enhanced CT scan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!